Predictive Oncology’s Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine
January 06 2021 - 8:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that its wholly owned subsidiary Helomics has
completed the integration of Quantitative Medicine’s (QM) novel
active-learning Computational Research Engine (CoRE™) with
Helomics’ proprietary TumorSpace™ knowledgebase of 150,000 tumor
drug response profiles and the TruTumor™ patient primary tumor cell
line assay. This integration allows Helomics to offer a
revolutionary new AI-driven patient-centric drug discovery service
to Pharmaceutical companies that will significantly improve the
chances of successfully translating new drugs into the clinic.
“With the completion of the CoRE integration, we are now able to
offer our new PeDAL™ (Patient-cEntric Discovery by Active Learning)
service to Pharmaceutical companies to allow patient-centric
de-risking of compounds early in discovery, resulting in better
prioritization of compounds and better coverage of patient
diversity. This will dramatically improve the chances of
successfully translating discoveries into the clinic, resulting in
lowered costs, shortened timelines, and most importantly enhanced
"speed-to-patient" for new therapies,” explained Dr. Carl Schwartz,
Predictive Oncology, CEO. “We expect to see revenue generating
projects that use PeDAL and CoRE in the first half of 2021,”
commented Dr. Schwartz.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify forward-
looking statements, although not all forward-looking statements
contain these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements as a result of a variety of factors including, among
other things, factors discussed under the heading “Risk Factors” in
our filings with the SEC. Except as expressly required by law, the
Company disclaims any intent or obligation to update these
forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024